BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo
March 06, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., March 06, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease
March 02, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., March 02, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces “BioVie Day” to be held March 23, 2023
February 21, 2023 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Issues Letter to Shareholders
December 07, 2022 08:00 ET
|
BioVie, Inc.
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented at the Clinical Trials in Alzheimer’s Disease...
BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia
December 06, 2022 06:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
December 05, 2022 17:00 ET
|
BioVie, Inc.
NE3107-treated patients experienced greater motor control in Parkinson’s trial Patients treated with the combination of NE3107 and levodopa saw improvements in their UPDRS Part 3 (motor) score that...
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
November 29, 2022 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting
November 15, 2022 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022
October 24, 2022 08:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
October 19, 2022 06:00 ET
|
BioVie, Inc.
CARSON CITY, Nev., Oct. 19, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...